Trial Profile
A Phase 1 Open-label Study Investigating the Excretion Balance, Pharmacokinetics, and Metabolism of a Single Oral Dose of [14C/12C]-Labeled Fenebrutinib in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Oct 2018
Price :
$35
*
At a glance
- Drugs Fenebrutinib (Primary)
- Indications Autoimmune disorders; Rheumatoid arthritis; Systemic lupus erythematosus; Urticaria
- Focus Adverse reactions
- Sponsors Genentech; Roche
- 25 Sep 2018 Status changed from recruiting to completed.
- 30 Jul 2018 New trial record